Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,932 recruiting studies in this area right now.
By phase
- Not applicable2,031
- Phase 21,075
- Phase 1791
- Phase 1/Phase 2481
- Phase 3345
- Phase 4125
- Phase 2/Phase 384
Top conditions
- Multiple Myeloma328
- Acute Myeloid Leukemia279
- Lymphoma179
- Sickle Cell Disease134
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia96
- Follicular Lymphoma70
- Hematologic Malignancy67
- Hodgkin Lymphoma64
- Myelodysplastic Syndrome64
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm54
- Lymphedema49
- Acute Myeloid Leukemia (AML)48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center62
- City of Hope Medical Center58
- Mayo Clinic56
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital45
- Peking University People's Hospital43
Where studies are running
- California397
- Texas185
- Alabama157
- Maryland152
- Arizona127
- Massachusetts105
- Florida104
- New York96
- Ohio72
- Minnesota69
Recruiting studies4,932 total
- NCT05892393RecruitingPhase 1
Scan test to find CD46-positive multiple myeloma lesions
This Phase 1 study tests a new special scan marker (a radioactive imaging agent) to see whether it can detect certain multiple myeloma spots in the body. If it works, it may help doctors better locate disease using a PET-style scan.
San Francisco, CaliforniaAges 18 years+ - NCT05901974RecruitingPhase 2
Venetoclax plus azacitidine for newly diagnosed ALAL
This Phase 2 study tests whether venetoclax combined with azacitidine can help people with ALAL (an “ambiguous” type of acute leukemia). It also checks whether the combination is safe for newly diagnosed patients with adequate heart, liver, and kidney health.
SuzhouAges 15 years+ - NCT05881447Recruiting
Study kidney disease patterns in people in Tanzania
This study looks at how common chronic kidney disease is, how it develops over time, and what risk factors are linked to it. It may help improve how kidney disease is recognized and managed in your community.
Bagamoyo, Coast RegionAges 18–99 - NCT05898477Recruiting
Studying treatment responses in lymphoma-related HLH
This trial looks at how people with lymphoma-related hemophagocytic lymphohistiocytosis (HLH) respond to treatment. It aims to better describe expected outcomes and who benefits most, which may help guide future care.
Birmingham, AlabamaAges Any age - NCT05890677Recruiting
Surgery versus conservative care for chronic breast-related arm swelling
This trial compares microsurgery to standard conservative therapy for long-lasting arm swelling caused by prior breast cancer. It may help people who still have swelling despite months of decongestive treatment by improving quality of life.
New Haven, ConnecticutAges 18 years+ - NCT05892718RecruitingPhase 1
Testing an immune drug for hard-to-treat cancers
This early-phase study tests HCB101, an immune-targeting drug, to see if it is safe and can shrink certain solid tumors or non-Hodgkin lymphoma. It may help people whose cancer has returned or stopped responding to standard treatments.
Port Saint Lucie, FloridaAges 18 years+ - NCT05879757Recruiting
Real-world HyQvia use for adults with myeloma and weak immunity
This study looks at how HyQvia (an immune-boosting medicine given under the skin) is used in real life for adults with multiple myeloma and secondary immune problems. It may help doctors understand what works best and how patients do when HyQvia is used routinely.
CórdobaAges 18 years+ - NCT05907057RecruitingPhase 3
Ivosidenib plus azacitidine for newly diagnosed AML
This trial studies ivosidenib together with azacitidine in people newly diagnosed with AML that has an IDH1 R132 gene mutation. It’s meant for patients who are not able to safely receive the strongest (intensive) chemotherapy, with the goal of improving control of the leukemia.
ViennaAges 18 years+ - NCT05889806Enrolling by invitation
Study uses blood and tissue samples for gene and protein testing
This study collects and analyzes your donated samples (like blood or other biospecimens) to look for patterns in genes and proteins. The results may help researchers understand disease biology and improve future tests or treatments.
New Orleans, LouisianaAges 18 years+ - NCT05741359RecruitingPhase 1
Study of BRL-201 for hard-to-treat aggressive B-cell lymphoma
This Phase 1 study tests BRL-201 (an anti-CD19 treatment) for safety and early signs of effectiveness in adults with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. It may help people whose lymphoma has returned or not responded to prior treatments.
Wuhan, HubeiAges 18 years+ - NCT05850273Recruiting
Study how interferon works in blood cancer patients
This study looks at how a medicine called pegylated interferon affects “myeloproliferative neoplasms” (MPNs), a group of slow-growing blood cancers. You may be included whether your MPN is newly diagnosed or already being treated, mainly to help researchers understand the treatment’s effects.
Villejuif, Île-de-France RegionAges 18 years+ - NCT05868499Enrolling by invitationPhase 1
Study follow-up for people who finished the first trial
This Phase 1 study is a follow-up “rollover” for people who already completed the 12-month visit of an earlier study. It checks what happens next after that prior study and may help doctors understand the ongoing safety and effects of the treatment.
Cincinnati, OhioAges 18 years+ - NCT05850234RecruitingPhase 1/Phase 2
Study drug for hard-to-treat multiple myeloma after prior treatments
This Phase 1/2 study tests AZD0120 in people with multiple myeloma that has come back or is not responding to treatment. It may help by targeting the myeloma cells after you’ve already tried several standard therapies.
Birmingham, AlabamaAges 18 years+ - NCT05862012RecruitingPhase 1
Test drug ISB 2001 in multiple myeloma patients who relapsed
This Phase 1 study tests ISB 2001, a new investigational treatment, in people with multiple myeloma that has come back or not responded to prior treatment. It mainly focuses on safety and whether the drug can be given effectively.
Palo Alto, CaliforniaAges 18 years+ - NCT05871970RecruitingPhase 2
TARA-002 treatment for lymphatic cysts in children
This Phase 2 trial tests whether an injected medicine called TARA-002 placed inside lymphatic cysts can safely shrink lymphatic malformations in children. It may help especially when the cysts are mainly in the head, neck, or chest area.
Birmingham, AlabamaAges 6 months–18 years - NCT05876312RecruitingPhase 1/Phase 2
Study drug ADX-038 in healthy people and PNH patients
This early-stage study tests how safe and tolerable ADX-038 is, and how the body processes it, in healthy volunteers and in people with paroxysmal nocturnal hemoglobinuria (PNH). It may help researchers understand whether the drug works safely for PNH patients and identify the right dosing.
Brisbane, QueenslandAges 18 years+ - NCT05874843Recruiting
Testing a bedside blood clot test in children
This trial checks whether a bedside machine (TEG 6s) can measure blood clotting in children during planned surgery. It may help doctors get faster, more accurate information about clotting during the operation.
Indianapolis, IndianaAges 3 months–18 years - NCT05847569RecruitingPhase 2
Testing alternating doses of belantamab for hard-to-treat myeloma
This Phase 2 trial tests whether alternating doses and schedules of belantamab mafodotin can help people with multiple myeloma that has returned or kept progressing after several prior treatments. You may be eligible if your disease has specific measurable signs and your blood counts and organs are healthy enough for study treatment.
Jacksonville, FloridaAges 18 years+ - NCT05868525RecruitingPhase 4
Compare two aspirin doses after blunt vessel injury
This trial tests whether taking a lower-dose aspirin (81 mg) works as well as a higher-dose aspirin (325 mg) to prevent stroke after a blunt injury that affects blood vessels in the neck/head. It may help some patients lower their stroke risk with the simplest, safest dose.
Loma Linda, CaliforniaAges 18 years+ - NCT05873712RecruitingPhase 2
Zanubrutinib plus CAR-T for Richter syndrome
This Phase 2 trial tests whether a combination of zanubrutinib (an oral medicine) and CAR-T cell therapy can treat Richter syndrome, a type of lymphoma that develops in people with CLL/SLL. It may help shrink tumors and improve outcomes after the disease comes back or doesn’t respond to prior treatment.
New York, New YorkAges 18 years+ - NCT05866757Recruiting
Stopping maintenance treatment in multiple myeloma patients
This study looks at whether it is safe to stop “maintenance” treatment for people with multiple myeloma who have been in remission for a long time, including those who stopped early because of side effects. It tests whether stopping therapy affects disease control and helps reduce ongoing treatment burden.
Cork, IrelandAges 18 years+ - NCT05873608Recruiting
Studies communication about cancer immunotherapy
This study looks at how patients and providers talk with each other about immunotherapy at Winship Cancer Institute. It may help improve communication and support for cancer care.
Atlanta, GeorgiaAges Any age - NCT05848687RecruitingPhase 1/Phase 2
Newborns with CD19 leukemia may try a combined infant therapy
This early-phase study is testing a “total therapy” treatment plan for very young babies (diagnosed within the first year of life) with certain types of leukemia that carry the CD19 marker. It may help find safer and more effective treatment for infants with this disease, especially soon after diagnosis.
Phoenix, ArizonaAges Up to 1 year - NCT05848765RecruitingPhase 2
Trial for relapsed follicular lymphoma after prior chemo
This Phase 2 trial studies treatment options for follicular lymphoma that has returned or did not respond to prior therapy. It compares a standard chemotherapy approach against another study treatment to see which works better and is tolerable.
AberdeenAges 18 years+
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,932 recruiting hematology studies from the U.S. registry right now, out of 7,407 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.